Last reviewed · How we verify
Hemabate
At a glance
| Generic name | Hemabate |
|---|---|
| Sponsor | Dongyu Wang |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNINGS HEMABATE Sterile Solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. HEMABATE should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.
Common side effects
- Vomiting
- Diarrhea
- Nausea
- Temperature increase
- Flushing or hot flashes
- Nervousness
- Nosebleed
- Sleep disorders
- Dyspnea
- Chills or shivering
- Tightness in chest
- Coughing
Serious adverse events
- Septic shock
- Uterine rupture
- Perforated uterus
- Pulmonary edema
- Thyroid storm
- Anaphylactic shock
- Anaphylactic reaction
- Angioedema
- Endometritis
- Retained placental fragment
Key clinical trials
- Cooling the Uterus in C-section After Dysfunctional Labor (NA)
- Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial (PHASE4)
- Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium (NA)
- Carboprost (Hemabate) for Fibroid Resection (EARLY_PHASE1)
- Oxytocin Bolus Versus Infusion in Elective Cesarean Section" (PHASE4)
- The Time Point of Carboprost Methylate Administration and Perioperative Complications (NA)
- Misoprostol Versus Active Management of Labour in CS (PHASE1)
- Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hemabate CI brief — competitive landscape report
- Hemabate updates RSS · CI watch RSS
- Dongyu Wang portfolio CI